Sources
Help build the largest human-edited directory on the web.
Submit a site - Become an editor
Wikipedia. Licensed under the GNU Free Documentation License.
Are you an expert in this subject? Join the discussion and share your knowledge at Wikipedia.org.
Sertoli-Leydig cell tumour
From Wikipedia, the free encyclopedia
| ICD-9 | 183.0, 256.1 |
|---|---|
| ICD-O: | 8631/0 |
| ICD-O: | 8630 |
|---|
Sertoli-Leydig cell tumour, also known as arrhenoblastoma, is a member of the sex cord-stromal tumour group of ovarian and testicular cancers. The tumour is rare, comprising less than 1% of ovarian tumours,[citation needed]. While the tumour can occur at any age, it occurs most often in young adults.
Contents |
The tumour is subdivided into many different subtypes. The most typical is composed of tubules lined by Sertoli cells and interstitial clusters of Leydig cells.
Due to excess testosterone secreted by the tumour, one-third of female patients present with a recent history of progressive masculinization. Masculinization is preceded by anovulation, oligomenorrhea, amenorrhea and defeminization. Additional signs include acne and hirsutism, voice deepening, clitoromegaly, temporal hair recession, and an increase in musculature. Serum testosterone level is high.
A recent study has shown that CD56 can be a marker for tumors of this class.[1]
Treatment consists of surgical resection alone with a unilateral salpingo-oophorectomy. The prognosis is generally good as the tumour tends to grow slowly and usually is benign: 25% are malignant.[citation needed]
- ^ McCluggage WG, McKenna M, McBride HA (2007). "CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors". Int. J. Gynecol. Pathol. 26 (3): 322–7. doi:10.1097/01.pgp.0000236947.59463.87. PMID 17581419.
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |